BMS-813160 + BMS-813160 + BMS-813160 + BMS-813160 + BMS-813160 + BMS-813160 + [14C] BMS-813160 + Placebo + BMS-813160 + BMS-813160

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Accelerated Intimal Hyperplasia

Conditions

Accelerated Intimal Hyperplasia

Trial Timeline

Feb 1, 2010 → Nov 1, 2010

NCT ID

NCT01049165

About BMS-813160 + BMS-813160 + BMS-813160 + BMS-813160 + BMS-813160 + BMS-813160 + [14C] BMS-813160 + Placebo + BMS-813160 + BMS-813160

BMS-813160 + BMS-813160 + BMS-813160 + BMS-813160 + BMS-813160 + BMS-813160 + [14C] BMS-813160 + Placebo + BMS-813160 + BMS-813160 is a phase 1 stage product being developed by Bristol Myers Squibb for Accelerated Intimal Hyperplasia. The current trial status is completed. This product is registered under clinical trial identifier NCT01049165. Target conditions include Accelerated Intimal Hyperplasia.

What happened to similar drugs?

0 of 1 similar drugs in Accelerated Intimal Hyperplasia were approved

Approved (0) Terminated (0) Active (1)

🔄dasatinib + dasatinibBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01049165	Phase 1	Completed	Feb 1, 2010	Nov 1, 2010	Accelerated Intimal Hyperplasia

Competing Products

4 competing products in Accelerated Intimal Hyperplasia

See all competitors

Product	Company	Stage	Hype Score
Blinatumomab + Cytarabine + Methotrexate + Ponatinib	Amgen	Phase 2	42
Pacritinib + Decitabine + Decitabine and Cedazuridine + Azacitidine	Swedish Orphan Biovitrum	Phase 2	42
dasatinib + dasatinib	Bristol Myers Squibb	Phase 3	40
Ruxolitinib + Enasidenib	Incyte	Phase 2	32